You are here: news / spectrascience initiates sales training with pentax in germany and belgium

SpectraScience Initiates Sales Training With PENTAX in Germany and Belgium

SAN DIEGO, CA--(Marketwire - Sep 27, 2012) - SpectraScience, Inc. ( OTCQB : SCIE ), a San Diego-based medical device company, recently completed training of the PENTAX Europe sales teams in Germany and Belgium on the WavSTAT4 Optical Biopsy System. The sales training effort follows the successful completion of training PENTAX technicians on the installation and maintenance of WavSTAT units at hospitals in several countries in Europe.

In addition to the sales training, WavSTAT technology was demonstrated in the PENTAX booth at the German Society of Digestive and Metabolic Disease Conference in Hamburg, September 19-22. The conference was attended by leading gastroenterologists and abdominal surgeons, and represented the first opportunity to feature WavSTAT at a major professional event in Germany.

"Our sales training program in Europe is off to a terrific start, and we are moving forward in other countries in the next few weeks," said Michael Oliver, SpectraScience's Chief Executive Officer. "The PENTAX Europe sales force is very enthusiastic regarding the prospects for WavSTAT, and the conference audience regarded it as an important addition to the PENTAX product portfolio. We believe WavSTAT will generate new revenue for PENTAX in existing accounts and, perhaps more importantly, also provide access to competitive accounts seeking a unique technology."

About SpectraScience, Inc.

SpectraScience is a San Diego-based medical device company that designs, develops, manufactures and markets light-based analysis systems capable of determining whether tissue is normal, pre-cancerous or cancerous without physically removing tissue from the body. The WavSTAT Optical Biopsy System uses light to optically diagnose tissue and provide the physician with an immediate analysis. With approval for sale under the CE Mark for the European Union, the WavSTAT System is the first commercially available product that incorporates this innovative technology for clinical use.

Forward-Looking Statements

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, acceptance of the Company's products and services in the marketplace, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.


SpectraScience, Inc.
Jim Dorst
Chief Financial Officer
(858) 405-9933

Investor Relations
Don Markley
Email Contact
(310) 691-7100
Spectra Science News